机构：[1]Department of Neurosurgery & Shenzhen Key Laboratory of Neurosurgery, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen 518035, China.[2]Department of Neurosurgery/ Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.临床科室其他部门神经外科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[3]Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.[4]College of Clinical Medicine, Anhui Medical University, Hefei 230032, China.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system. One of the most widely used chemotherapeutic drugs for GBM is temozolomide, which is a DNA-alkylating agent and its efficacy is dependent on MGMT methylation status. Little progress in improving the prognosis of GBM patients has been made in the past ten years, urging the development of more effective molecular targeted therapies. Hyper-activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is frequently found in a variety of cancers including GBM, and it plays a central role in the regulation of tumor cell survival, growth, motility, angiogenesis and metabolism. Numerous PI3K inhibitors including pan-PI3K, isoform-selective and dual PI3K/mammalian target of rapamycin (mTOR) inhibitors have exhibited favorable preclinical results and entered clinical trials in a range of hematologic malignancies and solid tumors. Furthermore, combination of inhibitors targeting PI3K and other related pathways may exert synergism on suppressing tumor growth and improving patients' prognosis. Currently, only a handful of PI3K inhibitors are in phase I/II clinical trials for GBM treatment. In this review, we focus on the importance of PI3K/Akt pathway in GBM, and summarize the current development of PI3K inhibitors alone or in combination with other inhibitors for GBM treatment from preclinical to clinical studies.
基金：
National Natural Science Foundation of China [81602195]; China Postdoctoral Science Foundation [2016M592588]; Shenzhen Science and Technology Innovation Commission [JCYJ20160425104157183, ZDSYS20140509173142601, GCZX2015050411225563]; Open Funds of State Key Laboratory of Oncology in South China [HN2016-09]; Fund of High Level Medical Discipline Construction in Shenzhen [2016031638]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区生化与分子生物学2 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区肿瘤学
第一作者：
第一作者机构：[1]Department of Neurosurgery & Shenzhen Key Laboratory of Neurosurgery, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen 518035, China.[2]Department of Neurosurgery/ Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
通讯作者：
通讯机构：[1]Department of Neurosurgery & Shenzhen Key Laboratory of Neurosurgery, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen 518035, China.[3]Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.
推荐引用方式(GB/T 7714)：
Zhao Hua-fu,Wang Jing,Shao Wei,et al.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development[J].MOLECULAR CANCER.2017,16(1):-.doi:10.1186/s12943-017-0670-3.
APA：
Zhao, Hua-fu,Wang, Jing,Shao, Wei,Wu, Chang-peng,Chen, Zhong-ping...&Li, Wei-ping.(2017).Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.MOLECULAR CANCER,16,(1)
MLA：
Zhao, Hua-fu,et al."Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development".MOLECULAR CANCER 16..1(2017):-
医学